Effect of TAAR1/5-HT(1A) agonist SEP-363856 on REM sleep in humans

por Hopkins, Seth C., Dedic, Nina, Koblan, Kenneth S.
Publicado 2021

Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophreni...

por Hopkins, Seth C, Ogirala, Ajay, Loebel, Antony, Koblan, Kenneth S
Publicado 2018

Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS

por Hopkins, Seth C., Ogirala, Ajay, Worden, MaryAlice, Koblan, Kenneth S.
Publicado 2021

Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D(2)-Based Pharmacological Class Effect Query Defined by FAERS

por Hopkins, Seth C., Ogirala, Ajay, Zeni, Courtney, Worden, MaryAlice, Koblan, Kenneth S.
Publicado 2022

Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia

por Achtyes, Eric D., Hopkins, Seth C., Dedic, Nina, Dworak, Heather, Zeni, Courtney, Koblan, Kenneth
Publicado 2023

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

por Galluppi, Gerald R., Polhamus, Daniel G., Fisher, Jeannine M., Hopkins, Seth C., Koblan, Kenneth S.
Publicado 2021

Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

por Hopkins, Seth C., Sunkaraneni, Soujanya, Skende, Estela, Hing, Jeremy, Passarell, Julie A., Loebel, Antony, Koblan, Kenneth S.
Publicado 2015

Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults

por Koblan, Kenneth S, Hopkins, Seth C, Sarma, Kaushik, Jin, Fengbin, Goldman, Robert, Kollins, Scott H, Loebel, Antony
Publicado 2015

Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders

por Hopkins, Seth C., Wilkinson, Scott, Corriveau, Taryn J., Nishikawa, Hiroyuki, Nakamichi, Keiko, Loebel, Antony, Koblan, Kenneth S.
Publicado 2021

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study

por Correll, Christoph U., Koblan, Kenneth S., Hopkins, Seth C., Li, Yan, Heather Dworak, Goldman, Robert, Loebel, Antony
Publicado 2021

The rate of dasotraline brain entry is slow following intravenous administration

por Lew, Robert, Constantinescu, Cristian C., Holden, Daniel, Carson, Richard E., Carroll, Vincent, Galluppi, Gerald, Koblan, Kenneth S., Hopkins, Seth C.
Publicado 2020

Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study

por Wigal, Sharon B., Hopkins, Seth C., Koblan, Kenneth S., Childress, Ann, Kent, Justine M., Tsai, Joyce, Hsu, Jay, Loebel, Antony, Goldman, Robert
Publicado 2019

Absorption, distribution, metabolism, and excretion of [(14)C]‐dasotraline in humans

por Chen, Yu‐Luan, Skende, Estela, Lin, Jing, Yi, Yijun, Wang, Peter L., Wills, Sarah, Wilkinson, H. Scott, Koblan, Kenneth S., Hopkins, Seth C.
Publicado 2016

KCTD12 modulation of GABA(B) receptor function

por Li, Melody, Milligan, Carol J., Wang, Haiyan, Walker, Andrew, Churilov, Leonid, Lawrence, Andrew J., Reid, Christopher A., Hopkins, Seth C., Petrou, Steven
Publicado 2017

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia

por Tsukada, Hironobu, Milanovic, Snezana M., Darpo, Borje, Xue, Hongqi, Xiong, Kuangnan, Tripp, Emily, Lennek, Lisa, Worden, MaryAlice, Hopkins, Seth C., Galluppi, Gerald R.
Publicado 2023

Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo

por Hopkins, Seth C, Campbell, Una C, Heffernan, Michele L R, Spear, Kerry L, Jeggo, Ross D, Spanswick, David C, Varney, Mark A, Large, Thomas H
Publicado 2013

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

por Tsukada, Hironobu, Chen, Yu-Luan, Xiao, Guangqing, Lennek, Lisa, Milanovic, Snezana M., Worden, MaryAlice, Polhamus, Daniel G., Chiu, Yu-Yuan, Hopkins, Seth C., Galluppi, Gerald R.
Publicado 2023

ECG Evaluation as Part of the Clinical Pharmacology Strategy in the Development of New Drugs: A Review of Current Practices and Opportunities Based on Five Case Studies

por Darpo, Borje, Borin, Marie, Ferber, Georg, Galluppi, Gerald R., Hopkins, Seth C., Landry, Ishani, Lo, Arthur, Rege, Bhaskar, Reyderman, Larisa, Sun, Lei, Watanabe, Takao, Xue, Hongqi, Yasuda, Sally
Publicado 2022

Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

por Heffernan, Michele L. R., Herman, Lee W., Brown, Scott, Jones, Philip G., Shao, Liming, Hewitt, Michael C., Campbell, John E., Dedic, Nina, Hopkins, Seth C., Koblan, Kenneth S., Xie, Linghong
Publicado 2021

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy

por Perini, Francesca, Nazimek, Jadwiga Maria, Mckie, Shane, Capitão, Liliana P., Scaife, Jessica, Pal, Deepa, Browning, Michael, Dawson, Gerard R., Nishikawa, Hiroyuki, Campbell, Una, Hopkins, Seth C., Loebel, Antony, Elliott, Rebecca, Harmer, Catherine J., Deakin, Bill, Koblan, Kenneth S.
Publicado 2023